Advertisement

Picture Demy-Colton BioFuture 2024 NYC Reimagine Healthcare 650x100px
Document › Details

Noscendo GmbH. (4/22/24). "Press Release: Labor Dr. Wisplinghoff Partners with Noscendo – NGS-based Pathogen Diagnostics now an Established Part of Their Service Portfolio".

Organisations Organisation Noscendo GmbH
  Organisation 2 Labor Dr. Wisplinghoff (Köln)
Products Product diagnostic services
  Product 2 DISQVER® fast digital NGS-based diagnostic pathogen test
Persons Person Stevens, Philip (Noscendo GmbH 201811 Managing Director + Co-Founder)
  Person 2 Haug, Peter (Oncgnostics GmbH 201501 Business Development + Licensing Manager)
     


Labor Dr. Wisplinghoff, a leading medical diagnostic laboratory in Germany with headquarters in Cologne, has been partnering with Noscendo GmbH for more than 1 year. The partnership now offers physicians and patients easy access to the fast digital diagnostic platform DISQVER®.

DISQVER® harnesses the power of Next-Generation Sequencing (NGS) and bioinformatics to identify more than 1,500 described pathogens from a single blood sample. The DISQVER® results may help physicians to treat seriously ill patients quicker and in a more targeted manner compared to traditional microbiology techniques.1

DISQVER® can identify more than 15,000 microbes, including 1,500 described pathogenic bacteria, DNA viruses, fungi and parasites, in just one blood sample – even after or during anti-infective therapy. This is made possible by Next-Generation Sequencing (NGS) of cell free DNA (cfDNA): After the cell-free DNA in the patient's blood has been sequenced, DISQVER® compares this information via bioinformatic algorithms with the clinical grade genome database of Noscendo. The result is a precise analysis of all relevant pathogens contained in the blood. The broad spectrum of detected microbes leads to a higher sensitivity and specificity of DISQVER® compared to blood culture. This reveals more clinically relevant positives and provides an upfront ‘rule out’ assay to exclude infectious aetiologies.1,2 Since no cultivation is required, the processing time from receipt in the laboratory to the result has already been less than 24 hours. Noscendo’s cooperation with Labor Dr. Wisplinghoff has enabled further reduction in the logistics and processing times for the DISQVER® test, particularly in the North Rhine-Westphalia region of Germany.

"We are pleased to provide our physicians and their patients with DISQVER®, the first NGS-based pathogen test. With this pioneering diagnostic method, we are underlining our ambition to be an innovative, reliable partner for doctors. The integration of DISQVER® into our processes has brought benefits for all sides", says Professor Dr. Hilmar Wisplinghoff, medical specialist for microbiology, virology and infection epidemiology.

Dr. Philip Stevens, CEO of Noscendo, adds: "In 2017, Noscendo began to bring diagnostics into the 21st century. By cooperating with strong partners such as the Labor Dr. Wisplinghoff, we are increasing the availability of DISQVER® for clinics, physicians, and patients. This helps us to achieve our goal: to support physicians in their therapy decisions in the best possible way and thus save lives."


ABOUT NOSCENDO

Noscendo GmbH is the leading European provider of NGS-based diagnostics for infectious diseases affecting critically ill patients. The approximately 50 employees in Duisburg and Tübingen-Reutlingen aim to revolutionise infection diagnostics and thus save patients' lives. Many renowned university hospitals, large regional clinics and hospital groups are already using DISQVER®. In addition, the diagnostics company Noscendo cooperates with health insurance companies such as the TK and the IKK Südwest within the framework of a selective contract as well as with the AOK Rheinland/Hamburg, the BARMER and the Techniker Krankenkasse (TK) as part of a project of the innovation fund of the Gemeinsamer Bundesausschuss (G-BA). Noscendo was named a Health-i Pioneer 2020 by Handelsblatt and TK. The award recognises particularly innovative ideas in the health sector.


ABOUT LABOR DR. WISPLINGHOFF

Labor Dr. Wisplinghoff improves patient care by providing highest quality laboratory diagnostics to hospitals, medical practices, universities, health departments and other medical entities 24/7/365. Founded in 1977 by Dr. Uta Wisplinghoff, it has become one of the largest independent private medical laboratories in Western Europe. Based in Cologne, Germany, the laboratory provides its comprehensive testing capabilities to national and international clients covering all areas of clinical pathology with experienced board-certified medical specialists.


Media Contacts:

Dr. Peter Haug
Chief Strategy Officer & Co-Founder
Noscendo GmbH
peter.haug@noscendo.com
www.noscendo.com

Cornelia Bartel
Head of Communications & Marketing
Labor Dr. Wisplinghoff
c.bartel@wisplinghoff.de
www.wisplinghoff.de

   
Record changed: 2024-06-05

Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for Noscendo GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px




» top